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Background. Vaccination is a cost-effective counter-measure to the threat of seasonal or pandemic outbreaks of influenza. To
address the need for improved influenza vaccines and alternatives to egg-based manufacturing, we have engineered an
influenza virus-like particle (VLP) as a new generation of non-egg or non-mammalian cell culture-based candidate vaccine.
Methodology/Principal Findings. We generated from a baculovirus expression system using insect cells, a non-infectious
recombinant VLP vaccine from both influenza A H5N1 clade 1 and clade 2 isolates with pandemic potential. VLPs were
administered to mice in either a one-dose or two-dose regimen and the immune responses were compared to those induced
by recombinant hemagglutinin (rHA). Both humoral and cellular responses were analyzed. Mice vaccinated with VLPs were
protected against challenge with lethal reassortant viruses expressing the H5N1 HA and NA, regardless if the H5N1 clade was
homologous or heterologous to the vaccine. However, rHA-vaccinated mice showed considerable weight loss and death
following challenge with the heterovariant clade virus. Protection against death induced by VLPs was independent of the pre-
challenge HAI titer or cell-mediated responses to HA or M1 since vaccinated mice, with low to undetectable cross-clade HAI
antibodies or cellular responses to influenza antigens, were still protected from a lethal viral challenge. However, an apparent
association rate of antibody binding to HA correlated with protection and was enhanced using VLPs, particularly when
delivered intranasally, compared to rHA vaccines. Conclusion/Significance. This is the first report describing the use of an
H5N1 VLP vaccine created from a clade 2 isolate. The results show that a non-replicating virus-like particle is effective at
eliciting a broadened, cross-clade protective immune response to proteins from emerging H5N1 influenza isolates giving rise
to a potential pandemic influenza vaccine candidate for humans that can be stockpiled for use in the event of an outbreak of
H5N1 influenza.
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INTRODUCTION
Vaccination is a potent and cost-effective counter-measure to the
threat of seasonal or pandemic outbreaks of influenza [1]. The
influenza virus is among the most devastating viral diseases due to
the ease of spread as an aerosol and ability to cause severe sickness
and mortality to susceptible humans. Currently licensed seasonal
influenza vaccines are only partially protective, particularly in
populations at highest risk of severe disease, the very young and the
elderly. In addition, there is a need for novel approaches for
enhancing immune responses to emerging influenza isolates of avian
origin harboring a potential of causing an influenza pandemic
outbreak that could infect and kill a considerable number of humans
over a short period of time. Enhanced immunity is particularly
important for vaccines protecting against such emerging strains,
since pre-clinical and clinical studies have shown that some of these
antigens such as those from H5N1 viruses are less immunogenic
than antigens from seasonal influenza subtypes (Reviewed in: [1–
4]). Recent research, however, has shown improved immunogenic-
ity of some H5N1 antigens if supplemented with proprietary
adjuvants [5]. If such approaches are shown to be well-tolerated in
humans, they might also be able to stretch the limited supply of
currently stockpiled vaccines. However, more research is needed in
the discovery of novel vaccines, adjuvants, and dosing regimens to
be able to supply the world with a safe and effective vaccine against
avian influenza viruses.
The next influenza pandemic may be caused by an avian H5N1
influenza subtype virus [1]. In 1997, 18 confirmed cases of human
infection with avian influenza A H5N1 viruses were identified in
Hong Kong that resulted in six deaths [6]. These cases represented
the first confirmed human outbreak associated with H5N1
influenza virus infection and raised global concerns about the
occurrence of an influenza pandemic. This event led to intensive
epidemiological monitoring of potential avian virus infection(s) by
the World Health Organization (WHO) influenza surveillance
network. Since 2003, outbreaks of avian influenza A (H5N1) have
emerged and spread throughout southeast and central Asia, the
Middle East, Africa, and Europe. Human cases increased between
2004 through 2007, with some H5N1 isolates showing resistance
to antiviral drugs amantadine and rimantadine [7–10]. In
addition, a second clade of H5N1 (represented by A/Indonesia/
05/2005) has been identified with several subclades. Clade 2
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isolates are genetically and antigenically distinct from clade 1
isolates (i.e. A/Viet Nam/1203/2004). In addition, there is
evidence of limited human-to-human transmission by new isolates
H5N1 influenza [11].
In August, 2006, the WHO advised that the choice of H5N1
strains for development of candidate vaccines should be
representative of the distinct groups (clades) of viruses that have
been afflicting humans recently [12]. The recent 2005–2006
outbreaks in Indonesia that were from clade 2 H5N1 viruses have
already resulted in more than 50 human deaths and infected
poultry in 28 of Indonesia’s 33 provinces [13]. This raises the need
for new studies to assess safety, immunogenicity, priming, cross-
reactivity and cross-protection of vaccines against a H5N1 clade 2
virus.
To meet the demand for pandemic influenza preparedness and
surge capacity following a newly identified pandemic influenza
outbreak, our research group has developed a non-infectious
influenza virus-like particle (VLP) platform for emerging isolates
with pandemic potential [14]. These influenza VLP vaccines do
not require the use of any live influenza virus during the
development, manufacturing, or administration of these vaccines.
As an alternative to conventional egg-based and mammalian cell-
produced influenza vaccine approaches, these recombinant-based
VLP vaccines are produced with a baculovirus system, which is a
promising, innovative technology for efficient, safe, high-yielding
and low-cost commercial vaccines for influenza virus.
Recently, our group described the development of influenza A
H3N2 and H9N2 VLP vaccines comprised of only three influenza
virus proteins, hemagglutinin (HA), neuraminidase (NA), and
matrix 1 (M1) [14,15] expressed in insect cells. These vaccines
elicited high-titer antibodies that were efficacious in mice and
ferret models [14,15]. In this study, using a similar approach, VLP
vaccines were constructed for from H5N1 isolates represented by
A/Viet Nam/1203/2004 (clade 1) and A/Indonesia/05/2005
(clade 2). These investigational pandemic influenza vaccines were
composed of non-infectious, non-replicating VLPs that maintained
viral hemagglutination and neuraminidase activities. Each vaccine
candidate was evaluated in mice for the ability to elicit an humoral
and cell-mediated immune response in dose-sparing experiments,
without the addition of adjuvants, and compared to those induced
by baculovirus-derived recombinant HA (rHA) proteins. Vacci-
nation with H5N1 VLPs showed protection against homologous
challenge, as well as cross-clade protection from viruses repre-
senting both H5N1 clades 1 and 2 avian influenza.
MATERIALS AND METHODS
Propagation of H5N1 reassortant viruses
The H5 HA and N1 NA of the reassortant H5N1 2005 viruses
were derived from influenza A/VN/1203/2004 (VNH5N1-PR8/
CDC-RG; termed VN/04) and A/Indonesia/05/2005 (Indo/05/
2005(H5N1)/PR8-IBCDC-RG2; termed Indo/05) viruses and the
internal protein genes came from the A/Puerto Rico/8/1934
(PR8) donor virus (kindly provided by Ruben Donis, Influenza
Division, Centers for Disease Control and Prevention, Atlanta,
GA, USA). Each virus requires the addition of 0.5 mg/ml TPCK-
treated typsin to induce plaques in minimal essential medium
(MEM) containing 0.8% agarose on chick embryo fibroblasts
(CEF) or MDCK cells, as determined by Ruben Donis at the
CDC. These reassortant viruses administered intranasally are not
pathogenic to chickens (Ruben Donis, CDC, personal communi-
cation) or ferrets (personal observation). However, we determined
that when these viruses (Indo/05; 1.8610+5 pfu/ml and VN/04;
1.6610+4 pfu/ml) were administered in 50 ul volume to
anesthetized 8 week old BALB/c mice, both viruses caused severe
weight loss within 8 days and 100% of mice died from
complications associated with viral infection. Therefore, we used
these viruses as challenge viruses for assessment of vaccine efficacy.
Virus stocks for the reassortant viruses were propagated in the
allantoic cavity of 9- to 11-day-old embryonated specific pathogen-
free (SPF) hen’s eggs at 37uC. The allantoic fluids from eggs
inoculated with each virus was harvested 24 h post-inoculation
and tested for hemagglutinating activity. Eggs inoculated with
reassortant viruses were incubated at 33uC and were harvested
3 days post-inoculation. Infectious allantoic fluids were pooled,
divided into aliquots, and stored at 280uC until used for studies.
The 50% tissue culture infectious dose (TCID50) for each virus was
determined by serial titration of virus in Madin-Darby canine
kidney (MDCK) cells and calculated by the method developed by
Reed and Muench [16]. All experiments, including animal studies
with infectious reassortant viruses, were conducted using enhanced
BSL-2 containment procedures in laboratories approved for use by
the USDA and Centers for Disease Control and Prevention.
Animal experiments were approved by the National Institutes of
Health Animal Care and Use Committee.
Plaque Assay with and without Trypsin
MDCK cells plated in 6-well tissue culture plates were inoculated
with 0.1 ml of virus serially diluted in Dubecco’s modified Eagle’s
medium (DMEM). Virus was adsorbed to cells for 1 h, with shaking
every 15 min. Wells were overlaid with 1.6% w/v Bacto agar
(DIFCO, BD Diagnostic Systems, Palo Alto, CA, USA) mixed 1:1
with L-15 media (Cambrex, East Rutherford, NJ, USA) containing
antibiotics and fungizone, with or without 0.6 mg/ml trypsin (Sigma,
St. Louis, MO, USA). Plates were inverted and incubated for 2–
3 days. Wells were then overlaid with 1.8% w/v Bacto agar mixed
1:1 with 26Medium 199 containing 0.05 mg/ml neutral red, and
plates were incubated for two additional days to visualize plaques.
Plaques were counted and compared to uninfected cells.
Cloning of HA, NA, and M1 genes and the
generation of recombinant baculoviruses
The HA, NA, and M1 genes for the H5N1 VLP vaccine were
synthesized by GeneArt (Germany) based upon sequences
ISDN125873, ISDN125875, ISDN125876 [17] and followed by
cloning into E. coli bacmids (Fig. 1A), plaque-purification of
recombinant baculoviruses with HA, NA, and M1 genes in a single
vector and expression in Spodoptera frugiperda Sf9 insect cells (ATCC
CRL-1711) as previously described [14]. At 72 h post-transfection,
cells were harvested for VLP production and recovery of
recombinant baculoviruses in the culture medium. Particle expres-
sion was analyzed by sucrose gradient ultracentrifugation and SDS-
PAGE followed by Western blot and purification of VLPs were
essentially as previously described [14]. Indo/05 rHA (Lot# 31-10-
06) was purified from the supernatants of Sf9 insect cells in-house
and VN/04 rHA (Lot # 15-06-06) was purified from the
supernatants of Sf9 insect cells acquired from Protein Sciences
Corp., Meriden, CT, USA. Vaccines and protein were stored at 4uC
prior to use.
Baculovirus infections and purification of rHA and
VLPs
Spodoptera frugiperda (Sf9) insect cells (ATCC CRL-1711) were
maintained as suspension cultures in HyQ-SFX insect serum free
medium (HyClone, Logan, UT, USA) at 28uC. Plaque isolates
expressing influenza proteins were amplified by infecting Sf9 cells
H5N1 Influenza VLPs
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seeded in shaker flasks at 2610+6 cells/ml at a multiplicity of
infection (MOI) = 0.05. At 72 h post-infection, culture superna-
tants containing the recombinant baculoviruses were harvested,
clarified by centrifugation, and stored at 4uC. Titers of
recombinant baculovirus stocks were determined by agarose
plaque assay in Sf9 cells.
Particle expression was analyzed by sucrose gradient ultracentri-
fugation and chromatography followed by Western blot as described
by Pushko et al. [14]. Briefly, Sf9 cells were infected in 200 ml volume
for 72 h at a cell density of 2610+6 cells/ml with recombinant
baculoviruses at a MOI = 3. Expression was determined by SDS–
PAGE using 4–12% gradient polyacrylamide gels (Invitrogen,
Carlsbad, CA, USA) and Coomassie staining and by Western
blotting using antigen-specific sera (Fig. 1B). H5N1 specific sera
included rabbit polyclonal sera raised against influenza A/
Indonesia/05/2005 virus. Indo/05 rHA was purified from Sf9
insect cells following baculovirus infection. Briefly, rHA was
extracted with a non-ionic detergent from Sf9 cells then purified to
.99% using ion exchange and affinity chromatography.
VLPs were purified from Sf9 cells infected with baculovirus
vectors expressing Indo/05 HA, NA, and M1 or VN/04 HA, NA,
and M1 at an MOI 3 pfu/cells. Seventy-two hours post-infection,
cultures were clarified to remove the cells and supernatants
containing VLPs were concentrated by tangent flow filtration with
a 500,000 molecular weight hollow fiber filter, then the concentrate
was diafiltered against PBS. The diafiltered concentrate was
centrifuged for 18 hr at 5,0006g on 20–60% sucrose gradients
and the particles containing primarily VLPs and baculoviruses were
recovered from a band in the gradients at about 30% sucrose.
Separation of VLPs from baculoviruses was performed using ion
exchange chromatography. The purity of VLPs was measured by
scanning densitometry of SDS-PAGE using OneDscan system (BD
Biosciences, Rockville, MD, USA) (Fig. 1B). VLPs were also
analyzed for particle formation and the presence of hemagglutinin.
Samples were coated on carbon-coated gold grids, stained with 5%
solution of Ammonium Molybdate and air dried. A Zeiss 902 CEM
electron microscope, operated at 80 kV, and digitally acquired with
an Olympus Soft Imaging Solutions, GMBH. Mega View II digital
camera at 128061024 pixel resolution was used. HA spikes on the
surface of 100–200 nm particles were confirmed using immunogold
staining with rabbit anti-HA or control antibody as shown in Fig. 1C
left and right panels, respectively.
Single-radial-immunodiffusion (SRID) assay
A quantitative single-radial-immunodiffusion (SRID) assay was
performed essentially as described by Wood, et al. [18]. Briely, VLPs
(lot# 07-14-06-WV-1/2) was analyzed using standardized CBER
reagents: CBER Antibody (rg A/Vietnam/1203/1204 Lot # S-
APSI Feb 5 2005) and CBER Reference Antigen (RG A/Vietnam/
1203/1204). The Indo rHA (lot #301P) and the Indo VLPs were
treated with 1% Zwittergent detergent (Calbiochem, EMD Biosci-
ences, San Diego, CA, USA) just prior use. VLP samples were diluted
and allowed to diffuse overnight in 1% agarose containing a dilution
the anti-HA sheep reference serum. The agarose gel was stained with
Coomassie and the diameter (mm) of antigen-antibody precipitation
rings were measured with a micro comparator.
Animals and vaccinations
BALB/c mice (Mus musculus, females, 6–8 weeks of age) were
purchased from Harlan Sprague Dawley, (Indianapolis, IN, USA).
Mice, housed in microisolator units and allowed free access to food
and water, were cared for under USDA guidelines for laboratory
animals. For vaccination, mice were anesthetized with 0.03–
0.04 ml of a mixture of 5 ml ketamine HCl (100 mg/ml) and 1 ml
xylazine (20 mg/ml). Mice (8 mice per group) were vaccinated
Figure 1. Expression of H5N1 virus-like particles. A) Baculovirus construct for expression of influenza A/Indonesia/05/2005 (H5N1) VLPs. Indicated
are the polyhedrin promoters (PolH), polyadenylation signals, Tn7 regions, gentamicin resistance gene (Gm), and influenza genes (HA, hemagglutinin,
M1, matrix 1 protein, NA, neuraminidase); B). Scanning densitometry analysis of purified Indo/05 VLPs. A sample of purified VLPs (4 mg) was
electrophoresed on 4–12% polyacrylamide gel and stained with Coomassie blue (right panel, lane 3). A scanned image (left panel, lane 3) was used to
determine the relative optical density (OD) of HA, NA, and M1. Purity is = OD HA+NA+M1/OD Total in the lane. Purity of this lot of Indo/05 VLPs was
96%. The location of HA, NA, and M1 structural proteins are marked. C). Immunogold electron microsopy of purified Indo/05 VLPs. Left Panel. Primary
antibody: Influenza A H5N1 Anti-HA antibody (Biodesign). Secondary antibody: Goat anti-rabbit conjugated to 10 nm gold beads. Right Panel.
Control antibody and goat anti-rabbit secondary antibody conjugated to 10 nm gold beads. Bar represents 100 nm scale.
doi:10.1371/journal.pone.0001501.g001
H5N1 Influenza VLPs
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with 3 mg or 600 ng doses (based on HA content) of either rHA or
purified VLPs. Vaccines and protein were stored at 4uC prior to
use. Animals were monitored for survival and morbidity (i.e.
weight loss, ruffling fur, inactivity) weekly during the vaccination
regimen and each day during viral challenge.
Blood was collected from anethesized mice via the retro-orbital
sinus. Blood was transferred to a tube containing a serum
separator and clot activator and allowed to clot at room
temperature. Tubes were centrifuged and sera was removed and
frozen at 28065uC. All procedures were in accordance with the
NRC Guide for the Care and Use of Laboratory Animals, the
Animal Welfare Act, and the CDC/NIH Biosafety in Microbio-
logical and Biomedical Laboratories.
ELISPOT assays
Spleens and lungs were harvested (weeks 5 and 8) from vaccinated
mice and cells were isolated for ELISPOT assays, as previously
described [19,20]. Briefly, cells were depleted of erythrocytes by
treatment with ammonium chloride (0.1 M, pH 7.4). Following
thorough washing with PBS, cells were resuspended in RPMI
medium with 10% fetal bovine serum (cRPMI). Cell viability was
determined by trypan blue exclusion staining. The number of anti-
HA or anti-M1 specific murine IFN-c (mIFN-c) secreting cells was
determined by enzyme-linked immunospot (ELISPOT) assay (R &
D Systems, Minneapolis, MN, USA). Briefly, pre-coated anti-
mIFN-c plates were incubated (25uC for 2 h) with cRPMI (200 ml)
and then were incubated with cell suspensions from the spleen or
lungs (16106/well) isolated from vaccinated mice. Spleen or lung
cell suspensions were stimulated (48 h) with pools of peptides (BEI
Resources; 5ng/ml per peptide) representing the regions of
influenza HA (Fig. 2) or M1 proteins. Additional wells of cells
were stimulated with PMA (50 ng)/ionomycin (500 ng) or were
mock stimulated. In addition, IL-2 was added to all wells (10
units/ml). Plates were washed with PBS-Tween (3X) and were
incubated (25uC for 2 h) with biotinylated anti-mIFN-c and
incubated (4uC for 16 h). The plates were washed and incubated
(25uC for 2 h) with strepavidin conjugated to alkaline phosphatase.
Following extensive washing, cytokine/antibody complexes were
incubated (25uC for 1 h) with stable BCIP/NBT chromagen. The
plates were rinsed with dH2O and air dried (25uC for 2 h). Spots
were counted by an ImmunoSpot ELISPOT reader (Cellular
Technology Ltd., Cleveland, OH, USA).
Serological assays
A quantitative ELISA was performed to assess anti-HA specific
IgG or IgG isotypes in immune serum. Purified rHA (30 ng) was
Figure 2. Amino acid sequence of hemagglutinin. Top line represents the sequence for A/Indonesia/05/2005, which is the isolate used to generate
vaccines studied. Middle line represents the sequence for A/Thailand/2004, which is the isolate used to generate the peptides used for analysis.
Bottom line represents the consensus amino acid sequence between the two sequences. Boxed, colored areas represent regions included in each of
the 6 peptides pools (15-16 peptides per pool, 15mers overlapping by 11) used for stimulating splenocytes and lung cells in ELISPOTs. The location of
the single H2-kd peptide (HA518; (IYSTVASSL) is underlined in peptide pool 6.
doi:10.1371/journal.pone.0001501.g002
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used to coat each well of a 96-well plate as previously described
[21–24]. Plates were blocked (25uC for 2 hr) with PBS containing
Tween 20 (0.05%) and nonfat dry milk (5%) and then incubated
with serial dilutions of each serum sample (25uC for 2 hr).
Following thorough washing in PBS-Tween 20 (0.05%), samples
were incubated (25uC for 1 hr) with horseradish peroxidase (HRP)
rabbit anti-mouse IgG (1:5000) diluted in PBS-Tween 20 (0.05%)
and nonfat dry milk (5%). The unbound antibody was removed,
and the wells were washed. Strepavidin-HRP (1:7000) was diluted
in PBS-Tween 20 (0.05%) and incubated (25uC for 1 hr). Samples
were incubated with TMB substrate (1 hr), and the colorimetric
change was measured as the optical density (O.D., 405 nm) by a
spectrophotometer (Dynex Technologies, Chantilly, VA, USA).
The O.D. value of the age-matched naı¨ve sera was subtracted
from the samples using antisera from vaccinated mice. Results
were recorded as the geometric mean titer (GMT)6the standard
error (SE).
Surface plasmon resonance (SPR) analysis
To assess the binding properties of serum antibodies, SPR
technology was performed using a Biacore 3000 (Biacore AB,
Uppsala, Sweden). Protein A (Pierce, Rockford, IL, USA) was
immobilized to the surface of a CM5 sensor chip (Biacore, Inc.,
Piscataway, NJ, USA) using standard amine coupling chemistry.
The surface of the chip was activated using a 1:1 mixture of N-
hydroxysuccinimide and 1-ethyl-3-(3-dimethyl aminopropyl) car-
bodimide hydrochloride (EDC) (Biacore, Inc.) followed by a 20-
minute injection of protein A (70 mg/ml) to capture ,5000 RU of
protein A on two adjacent flowcells on a CM5 sensor chip.
Remaining active carboxyl groups were inactivated with an
injection of 1 m ethanolamine, and remaining non-covalently
associated protein A was washed from the surface using four 30
sed injections of 100 mm HCl (100 ml/min). The second flowcell
of the protein A-coated CM5 sensor chip was then used to capture
polyclonal IgG antibody from VLP or rHA vaccinated mice.
Serum was diluted in HBS-EP buffer such that a 5 ml injection at a
flow rate of 10 ml/min yielded ,100-300 RU total IgG antibody
captured by the protein A on the CM5 chip. After capture of IgG,
varying concentrations (0.7–300 nm, series of threefold dilutions)
of rHA representing the Indonesia/05/2005 or Viet Nam/1203/
2004 strains were passed sequentially over both flowcells of the
sensor chip. A blank (0 nm) injection was also included. Binding
isotherms were then analyzed using BiaEvaluation 4.1 (Biacore
AB). It is important to realize that kinetic rates returned using
these binding models for polyclonal serum represent only apparent
rates of binding due to the multiple specificities inherent to a
polyclonal response and do not define the kinetics of the polyclonal
antibody anti-HA antibody response.
Hemagglutination inhibition activity
The hemagglutination inhibition (HAI) assay was used to assess
functional antibodies to the HA able to inhibit agglutination of
horse erythrocytes. The protocol was adapted from the CDC
laboratory-based influenza surveillance manual [1]. To inactivate
non-specific inhibitors, sera were treated with receptor destroying
enzyme (RDE) prior to being tested [21–23,25,26]. Briefly, three
parts RDE was added to one part sera and incubated overnight at
37uC. RDE was inactivated by incubation at 56uC for ,30 min
and six parts PBS were added for a final 1:10 dilution of the sera.
RDE-treated sera was two-fold serially diluted in v-bottom
microtiter plates. An equal volume of reassortant virus, adjusted
to approximately 8 HAU/50 ml, was added to each well. The
plates were covered and incubated at room temperature for
20 min followed by the addition of 1% horse erythrocytes (HRBC)
(Lampire Biologicals, Pipersville, PA, USA) in PBS. Red blood
cells were stored at 4uC and used within 72 hours of preparation.
The plates were mixed by agitation, covered, and the RBCs were
allowed to settle for 1 h at room temperature [27]. The HAI titer
was determined by the reciprocal dilution of the last row which
contained non-agglutinated RBC. Positive and negative serum
controls were included for each plate. All mice were negative
(HAI#10) for pre-existing antibodies to currently circulating
human influenza viruses prior to vaccination [28].
Isolation of cells from spleen and lung tissue
Spleens and lungs were excised, carefully rinsed with sterile PBS,
and a single cell suspension was generated using a cell strainer (BD
Biosciences, Bedford, MA, USA). Collected cells were centrifuged
(10006g for 5 min at 4uC). The cells were gently resuspended in
5 ml of RBC lysis buffer and incubated for 5 min at RT. PBS
(5 ml) was added to each sample to neutralize RBC lysis buffer and
then the cells were centrifuged (10006g for 5 min at 4uC). The
supernatants were discarded, and the cells were then resuspended
in 3 ml of PBS. 200 ml of the cell suspension were aliquoted into
1.5 ml microcentrifuge tubes and stored at 280uC.
Protection from lethal viral challenge
Mice that received either the VLP or rHA antigen were challenged
with a lethal dose (10LD50) of one of the two H5N1 reassortant
viruses. To determine the lethal dose of each reassortant H5N1/
PR8 virus [16], mice were administered various dilutions of virus
(50 ml) via the nares under one of two conditions: light or deep
anesthetic. For light anesthetic, mice were administered a 1/10
dose of ketamine/xyalzine (as described above) that resulted in
mice that were anesthetized for ,5 minutes with light breathing.
Mice returned to a normal state in ,15 min. For deep anesthetic,
mice were administered full dose of ketamine/xyalzine that
resulted in mice being unconscious for greater than 30 min and
the mice returned to a normal state in ,1 h. Only, mice
challenged with reassortant viruses under deep anesthetic showed
signs of severe weight loss and mortality (data not shown). Mice
were monitored daily for clinical signs of influenza infection and
body weight was recorded each day. Mice that lost greater than
25% of body weight were euthanized. The ability of each vaccine
to protect against homologous or heterologous challenge was
compared to separate groups of naı¨ve, unvaccinated control mice
that were challenged with each reassortant virus.
Lung virus titers were determined using a plaque assay [29,30].
Briefly, lungs from mice infected with virus were collected and
single cell suspensions via passage through a 70 mM mesh (BD
Falcon, Bedford, MA, USA) in 4 ml of PBS. Cell suspensions were
frozen (280uC) for 1 h, and then thawed, centrifuged at 10006g
for 10 min, and then the supernatants were collected and stored at
280uC.
Madin-Darby Canine Kidney (MDCK) cells were plated
(56105) in each well of a six-well plate. Virus was diluted (1:100
to 1:1000) and overlayed onto the cells in 100 ul of DMEM
supplemented with penicillin-streptomycin and incubated for 1 hr.
Virus-containing medium was removed and replaced with 2 ml of
L-15 medium plus 0.8% agarose (Cambrex, East Rutherford, NJ,
USA) and incubated for 48 hrs at 37uC with 5% CO2. Agarose
was removed and discarded. Cells were fixed with 70% EtOH,
and then stained with 1% crystal violet for 15 min. Following
thorough washing in dH2O to remove excess crystal violet, plates
were allowed to dry, plaques counted, and the plaque forming
units (pfu)/ml were calculated.
H5N1 Influenza VLPs
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Statistical analysis
Statistical analyses were performed using a two-tailed t-test with
equal variance. Samples from VLP-vaccinated animals were
compared to rHA-vaccinated animals and significance was
considered at a p-value,0.05.
RESULTS
Cell-mediated immunity elicited by VLP and rHA
vaccines
Mice (BALB/c; n = 8) were vaccinated (week 0 and 3) via
intramuscular injection or intranasal inoculation with purified
influenza VLPs or purified rHA proteins representing the H5N1
isolate A/Viet Nam/1203/2004 (clade 1) or the A/Indonesia/05/
2005 (clade 2) isolate. Collected splenocytes and lung cells were
stimulated in vitro with pools of peptides specific for influenza
H5N1 isolates (Fig. 2). Mice vaccinated with the influenza VLPs
had a robust cell-mediated immune response against peptide pools
from either the HA (Fig. 3) or M1 (Fig. 4). Cell-mediated immune
responses were directed against epitopes in both the HA1 and
HA2 subunits in mice vaccinated with VLPs, however, only
peptides in pool 2 were recognized from rHA-vaccinated mice
(Fig. 3A and B). Splenocytes stimulated with an immunodominant
H-2d peptide (HA518) contained in pool 6 had as strong a
response as cells stimulated with the entire peptide pool 6. Only
VLP-vaccinated mice had cellular responses to M1 (Fig. 4).
Mice vaccinated with VLPs intranasally had cell-mediated
immune responses, as measured by mIFN-c production, in both
splenocytes and lung cells (Fig. 3C and D) however, mice
vaccinated with VLPs intramuscularly had a robust cellular
response in the spleen, but a limited cellular response in the lung.
There was a limited or undetectable cellular response from
isolated lung cells or splenocytes following vaccination with rHA
protein (intranasally or intramuscularly). The number of mIFN-c
secreting splenocytes from age-matched mice, as well as
splenocytes from mice vaccinated with VLPs and stimulated with
an irrelevant peptide or unstimulated was negligible (10–12 spots)
following in vitro re-stimulation (data not shown).
Antibody responses to immunizations
At week 5, mice vaccinated intramuscularly with VLPs or rHA
had anti-HA antibodies that recognized the homologous rHA-
coated plates with endpoint dilution titers that ranged between
104-105 (i.e. antibodies elicited by an Indonesia-derived vaccine
binding to HA in an Indonesia rHA-specific ELISA) (Table 1).
Mice vaccinated intranasally with Indonesia VLPs had an anti-HA
endpoint dilution titer against Indonesia rHA that ranged between
105-106. The homologous anti-HA antibody titer in Viet Nam
VLP vaccinated mice was 104-105, regardless of the route of
inoculation. In contrast, anti-HA antibodies were low or
undetectable in mice that received an intranasal inoculation of
rHA antigen. Each serum sample was also tested for binding to the
cross-clade HA in an ELISA. Interestingly, all serum samples that
detected a homologous HA, also detected the heterologous H5N1
HA protein, albeit at a lower titer. As previously reported for
H3N2 VLPs [15], the dominant serum IgG isotype subclasses
elicited in VLP-vaccinated mice were IgG2a and IgG2b, indicative
of a T helper type 1 response (Fig. 5A). In contrast to VLP
Figure 3. Elicitation of HA interferon-c producing splenocytes and lung cells. ELISpots were performed on isolated splenocytes or lung cells from
vaccinated mice (n = 8) collected at week 8. Cells (16106) were stimulated independently with pools of peptides representing different regions of HA.
Splenocytes or lung cells were also stimulated independently with pools of peptides (15mers overlapping by 11 amino acids) or a single peptide
HA518 (IYSTVASSL). Following stimulation, cells were assayed for mIFN-c. HIV-1 Env peptides were used as a non-specific negative control.
Splenocytes or lung cells stimulated with PMA/ionomycin were used as a positive control. (A) VLP vaccinated intramuscularly against all peptide
pools, (B) rHA vaccinated intramuscularly against all peptide pools, (C). Lung responses using HA peptide pool 2. (D). Spleen responses using HA
peptide pool 2.
doi:10.1371/journal.pone.0001501.g003
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vaccination, mice vaccinated with rHA elicited primarily an IgG1
(Th2) response. In a similar ELISA used to evaluate humoral
responses directed to the NA, only mice vaccinated with VLPs had
anti-NA antibodies (Table 2).
Vaccine induced hemagglutination-inhibition
activity
Antibodies elicited by each vaccine were evaluated for the ability
to inhibit virus-induced agglutination of horse red blood cells
(Table 3). At week 5, 100% of the mice vaccinated with either
clade 1 Viet Nam or clade 2 Indonesia VLPs had HAI titers$1:40
against a reassortant virus containing HA and NA surface proteins
matching the vaccine composition (homologous virus) (Table 3),
regardless of the route of inoculation. Six of eight (75%) mice
vaccinated intramuscularly with rHA had HAI titers greater than
$1:40, but none of the mice vaccinated intranasally with rHA had
a measurable HAI titer. HAI titers elicited by Indonesia clade 2
VLPs against the clade 2 reassortant virus were.1 log higher than
HAI titers elicited by Viet Nam clade 1 VLPs against the clade 1
reassortant virus. In contrast, serum from mice vaccinated with
Indonesia clade 2 VLPs had .1 log lower HAI titers against the
heterologous Viet Nam clade 1 reassortant virus compared to HAI
titers against the homologous clade 2 reassortant virus, regardless
the route of inoculation (Table 3). Viet Nam VLPs elicited similar
HAI titers against both the homologous clade 1 reassortant virus,
as well as the heterologous clade 2 reassortant virus.
Protection against heterologous H5N1 viral
challenge
Mice that received either H5N1 clade 1 or clade 2 vaccines or
unvaccinated control mice were challenged intranasally with a
predetermined lethal dose of either a reassortant homologous or
heterologous virus to evaluate the protective efficacy of each
vaccine candidate. All mice vaccinated intramuscularly or
intranasally with either VLP vaccine or intranasally only with
rHA vaccines were protected from death following the lethal
challenge of homologous virus whereas, all non-vaccinated, naı¨ve
mice lost greater than 25% of their original body weight and died
from complications associated with infection by day 6 post-
challenge (Fig. 6). Mice vaccinated with either VLP vaccine lost
Figure 4. Elicitation of M1 interferon-c producing splenocytes. ELISPOTs were performed as described in the legend to Fig. 3. Four pools (15mers,
overlapping by 11) representing four regions of M1 were used to stimulate cells. HIV-1 Env peptides were used as a non-specific negative control.
Splenocytes stimulated with PMA/ionomycin were used as a positive control. Number of IFN-c ELISPOTs detected using each of the four M1 peptide
pools from intramuscularly vaccinated mice with (A) VLP or (B) rHA vaccines.
doi:10.1371/journal.pone.0001501.g004
Table 1. Anti-HA Titer
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intramuscular Intranasal
Clade Vaccine (Dose)a VN/1203/2004b Indo/05/2005 VN/1203/2004 Indo/05/2005
Clade 1-Vietnam
VLP (3 ug) 200,000c 12,500 200,000 12,500
VLP (600 ng) 25,000 25,000 12,500 25,000
rHA (3 ug) 6,400 12,500 200 ,100
rHA (600 ng) 800 3,200 ,100 ,100
Clade 2-Indonesia VLP (3 ug) 12,500 200,000 400,000 2,000,000
VLP (600 ng) 25,000 200,000 25,000 200,000
rHA (3 ug) 3,200 12,500 ,100 400
rHA (600 ng) 1,600 6,400 ,100 400
Mock ,100 ,100 ,100 ,100
aDose based upon HA content
bIsolate from which the HA was used.
cAnti-HA GMT titer.
doi:10.1371/journal.pone.0001501.t001..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
H5N1 Influenza VLPs
PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1501
less than 5% of their original weight by day 6 following
homologous viral challenge, regardless of the route of inoculation.
In addtion, all VLP-vaccinated mice survived challenge, with little
weight loss, following heterologous challenge (i.e. Indonesia clade 2
VLP vaccinated mice were protected against Viet Nam clade 1
challenge). However, there was more pronounced weight loss in
mice vaccinated intramuscularly with either of the H5N1 rHA
antigens following heterologous challenge, even though all mice
survived. By day 21 post-challenge, all mice recovered to their
original body weight, despite little or no detectable serum HAI
antibodies against heterologous H5N1 virus prior to challenge
(Table 3). In contrast, all mice vaccinated intranasally with rHA
showed considerable weight loss and mortality similar tonaı¨ve
unvaccinated animals. Despite lower HAI titers compared to mice
vaccinated with clade 2 vaccines, similar results were observed
with mice vaccinated with Viet Nam VLPs and rHA vaccines
(data not shown).
Binding characteristics of serum antibody as
determined by surface plasmon resonance
In order to determine binding characteristics of polyclonal serum
antibodies using surface plasmon resonanace (SPR), recombinant
HA proteins, representing both H5N1 clades, were characterized
(Fig. 7). Serum samples were diluted, polyclonal IgG was captured,
and binding experiments were carried out as previously described
[31,32]. At week 5 post-vaccination, mice vaccinated intranasally
with VLPs had a more dynamic pattern of antibody responses
against the homologous HA antigen than mice vaccinated
intramuscularly with the same vaccine (Fig. 7). Mice vaccinated
with VLPs had one population of antibody that bound specifically
to each homologous HA at an apparent association rate (ka1) that
ranged from 1.556104 to 1.656105, regardless of the vaccine
strain (Viet Nam clade 1 or Indonesia clade 2) or the route of
vaccination (IM or IN). This apparent association rate was similar
to antibodies elicited by rHA following intramuscular injection
(1.136104). In contrast, the apparent dissociation rate (kd1) differed
between intranasally or intramuscularly vaccinated mice against
homologous HA. Following the boost, mice vaccinated intrana-
sally with Indonesia clade 2 VLPs had antibodies with an apparent
Figure 5. Anti-HA IgG Isotypes. The specific IgG isotype was assayed from the serum of each mouse group and the endpoint dilution titer was
reported. (A) Week 5, pre-challenge. (B) Week 7, post-challenge. Each bar represents the average of 8 mice.
doi:10.1371/journal.pone.0001501.g005
Table 2. Anti-NA Titer.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intramuscular Intranasal
Clade Vaccine (Dose)a Anti-NA Anti-NA
Clade 1-Vietnam VLP (3 ug) 1600b 800
rHA (3 ug) ,100 ,100
Clade 2-Indonesia VLP (3 ug) 3200 3200
rHA (3 ug) ,100 ,100
Mock ,100 ,100
aDose based upon HA content
bAnti-NA GMT titer at week 5.
doi:10.1371/journal.pone.0001501.t002..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
H5N1 Influenza VLPs
PLoS ONE | www.plosone.org 8 January 2008 | Issue 1 | e1501
Table 3. Hemagglutination-Inhibition Titer
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intramuscular Intranasal
Clade Vaccine (Dose)a VN/1203/2004b Indo/05/2005 VN/1203/2004 Indo/05/2005
Clade 1-Vietnam VLP (3 ug) 400665c* 80653** 256654 121620
VLP (600 ng) 121620 44610 30616 30629
rHA (3 ug) 46615 1060 1060 1060
rHA (600 ng) 139645 2266 1060 1060
Clade 2-Indonesia VLP (3 ug) 101627** 337761599* 80653* 33776809**
VLP (600 ng) 60610 8456202** 1262 19406314^
rHA (3 ug) 1060 2116100 1060 1060
rHA (600 ng) 1060 16060 1060 1060
Mock 1060 1060 1060 1060
aDose based upon HA content
bInfluenza viruses used in the HAI assay against sera collected at week 5.
cHAI GMT plus or minus SEM.
dVLP vs. rHA comparing same dose, t-test, *p,0.05, **p,0.01, ^p,0.001
doi:10.1371/journal.pone.0001501.t003..
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Figure 6. Protection from influenza virus challenge. At week 5, mice vaccinated with H5N1 clade 2-dervied vaccines were challenged intranasally
with a lethal dose of reassortant influenza virus (A/Viet Nam/1203/2004 (clade 1) or A/Indonesia/05/2005 (clade 2)) and monitored daily for weight
loss and mortality. The data are plotted as percentage of the average initial weight. Percentage of (A) original weight or (B) survival following
challenge with clade 2 AIndonesia/05/2005 reassortant virus. Percentage of (C) original weight or (D) survival following challenge with clade 1 A/Viet
Nam/1203/2004 reassortant virus. Mice that lost greater than 75% body weight were euthanized. Naı¨ve mice were unvaccinated.
doi:10.1371/journal.pone.0001501.g006
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dissociation rate of 2.1261025 compared to sera from intramus-
cularly VLP-vaccinated mice that had a dissociation rate of
1.7161023, which was similar to the dissociation rate from mice
vaccinated intramuscularly with Indonesia clade 2. rHA
(4.1161023) (Fig. 7). Surprisingly, there was little change in the
dissociation rate of VLP elicited antibodies when tested against the
heterologous Viet Nam clade 1 HA antigen (3.0161024), but a
significant decline in the association rate to the Viet Nam clade 1
HA (2.466102) compared to the Indonesia clade 2 HA. Similar
results were observed with sera from mice vaccinated with Viet
Nam clade 1 VLPs or rHA vaccines (data not shown). Therefore,
the ability of antibody to bind to the heterologous HA antigen
appears to be associated with the apparent association rate
compared to antibody binding to the homologous HA antigen.
Single vaccination elicits protection against
challenge
To determine if a single vaccination could elicit protective
immunity to a lethal viral challenge, a second set of mice were
vaccinated with a single intramuscular immunization (week 0) with
purified influenza Indo/05 VLPs or rHA proteins and the
responses were compared to mice vaccinated with two immuni-
zations (week 0 and 3). Mice vaccinated with a single
immunization of VLPs or rHA had no detectable HAI titers
during the 5 week regimen (data not shown), but survived a
challenge with 10LD50 of homologous reassortant Indonesia clade
2virus. Interestingly, mice vaccinated with the 3 ug dose of VLP
had little to no weight loss (Fig. 8), which was similar to mice
vaccinated with two doses of VLP or rHA vaccines (Fig. 4A).
However, mice vaccinated with lower doses of VLPs or rHA lost
,15% of their body weight by day 6 post-challenge, but recovered
by day 10 post-challenge (Fig. 8). Naı¨ve mice lost 80% of their
body weight by day 5 post-challenge and all mice died from
challenge by day 8.
Additional groups of vaccinated mice were euthanized on day 3
post-challenge and virus titers were determined from homogenized
lung tissue (Table 4). Mice vaccinated with two doses of VLPs (3 ug)
had no detectable Indo/05 virus (dilution 1:100) and no gross signs
of infection. Unvaccinated naı¨ve mice had an average titer of
1.566106 pfu/ml. These mice had ruffled fur, dyspnea, and lethargy
by day 6 post-challenge. Sixty-six percent of the mice vaccinated
with rHA (3 ug) had a detectable viral titer that was ,3 logs lower
than virus titers from unvaccinated mice (Table 4), but few gross
pathological signs. Interestingly, mice vaccinated with a single
immunization of VLPs had no detectable viral titers, whereas mice
vaccinated with rHA had an average titer of 4.56104.
DISCUSSION
Influenza virus-like particle vaccines described in this report are
non-replicating particle-based vaccine candidates for influenza
based upon a influenza A H5N1 clade 1 and 2 isolates. Our results
show that BALB/c mice immunized with VLP vaccines were
effectively protected from disease and death when challenged with
viruses with antigenically distinct HA and NA proteins from H5N1
influenza viruses. These results highlight the potential of VLP
vaccine as an effective immunogen and delivery system for
influenza antigens, particularly to the respiratory tract. Our VLPs
have the advantage of inducing strong humoral and cellular
immune responses against multiple influenza viruses without the
need of a supplemental adjuvant. The inclusion of the highly
Figure 7. Kinetics of Indonesia VLP elicited antisera binding to H5N1
rHA antigens. Kinetics of antisera binding to homologous, Indonesia
clade 2 rHA (black square) and heterologous, Viet Nam clade 1 rHA
(white square). Values on x-axis represent the apparent association rate
of antibody binding to HA and the values on the y-axis represent the
apparent disassociation rate of antibody from the HA antigen.
doi:10.1371/journal.pone.0001501.g007
Figure 8. Protection from influenza virus challenge. At week 5, mice vaccinated with clade 2-dervied vaccines were challenged intranasally with a
lethal dose of reassortant influenza virus (A/Indonesia/05/2005 (clade 2)) and monitored daily for weight loss and mortality. The data are plotted as
percentage of the average initial weight. Percentage of original weight (A) Mice vaccinated with two doses of vaccine (week 0 and 3) and (B) mice
vaccinated with a single dose of vaccine (week 0). All mice challenged at week 5. Mice that lost greater than 25% body weight were euthanized.
doi:10.1371/journal.pone.0001501.g008
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conserved M1 protein is also advantageous, since CD8+ T cells
against conserved epitopes within M1 can contribute to protection
against morbidity and mortality from influenza [33–38]. Pools of
peptides representing M1 were used to identify cellular responses
elicited by our VLPs (Fig. 4). In addition, these vaccines have the
potential to elicit protective immune responses as effectively as
live-attenuated influenza without safety issues associated with the
isolation, production, and delivery of live vaccines [4].
Currently licensed seasonal influenza vaccines elicit immunity that
is subtype- and sometimes strain-specific and do not protect against
avian H5N1 viruses with pandemic potential. Our influenza VLPs
are a new generation of egg-independent candidate vaccines
expressed from insect cells infected by a recombinant baculovirus
that encodes genes for three influenza virus proteins, HA, NA, and
M1 [14,15]. These VLPs may have an advantage over HA-only
based vaccines by the inclusion of these additional viral proteins,
especially against evolving H5N1 isolates from various clades. These
VLPs elicited anti-NA antibodies against an N1 NA protein that was
not matched to the vaccine. Antibodies against the same subtype of
NA, but not the exact NA molecule, can contribute to protective
immune responses [39]. When delivered via parenteral or mucosal
routes, VLPs may be particularly effective immunogens at priming T
cells and targeting antigen-presenting cells, as described for other
VLPs [40–43], as well as inducing high titered antibody responses
[44,45]. Another key factor is the authentic presentation of surface
HA and NA in native, three-dimensional conformation. Recent
clinical trials of human papillomavirus (HPV) VLPs have led to FDA
approval [46,47] and therefore, this may bode well for the approval
of additional VLP-based vaccines, including influenza VLPs. Our
influenza VLPs are easy to develop, produce, and manufacture.
They are not labor-intensive and they do not require costly
production schemes typically associated with manufacturing vac-
cines in eggs. VLP vaccines, like other recombinant influenza
vaccines, are particularly advantageous to address future pandemics
because these vaccines 1) need shorter lead times for development of
vaccines matched to circulating strains of viruses, 2) use recombinant
DNA technology to alleviate safety restrictions and bottlenecks
associated with dependence on live viruses, 3) use cell culture based
methods with disposable bioreactors to provide rapid response and
higher yields (scalable and transferable) for improved surge capacity.
In studies reported here, all mice vaccinated intramuscularly with
either vaccine or intranasally with the VLP vaccines survived
challenge with lethal doses of reassortant viruses. However,
intranasal delivery of the VLPs did elicit a broader immune response
than the same vaccine delivered intramuscularly. Cellular responses,
in particular, were reduced in the lung mucosa in mice vaccinated
intramuscularly compared to intranasally vaccinated mice. The
ability to elicit mucosal immune responses in the respiratory tract,
including the lungs, is desirable for an influenza vaccine.
Neutralization of influenza by pre-existing sIgA and IgG in the lung
reduces infection of susceptible epithelial cells [48–50] and thereby
reduces the deleterious effects induced by elevated cytokine levels,
which typically lead to the development of fever and respiratory
symptoms [51–53]. H5N1 infection in humans activates cytokine/
chemokine secretion resulting in the occurrence of a ‘‘cytokine
storm’’ that may contribute to the severity of disease by these viruses
[53–56]. The levels of these pro-inflammatory cytokines, triggered
by influenza gene products, are higher during H5N1 virus infection
compared to seasonal influenza virus infection [57]. Therefore,
vaccines, such as VLPs studied here, that prevent infection by
antibody or quickly clear infected cells by cell-mediated immune
responses [58–63] in the lung mucosa may blunt the activation of
this deleterious immune activation by reducing viral replication.
Compared to particulate antigens, intranasal vaccination of
soluble proteins, in the absence of an adjuvant, induces low or
undetectable immune responses in rodents and primates
[41,42,64]. In the nasal mucosa, VLPs are most likely phagocy-
tosed by microfold epithelial cells (M cells) in the nasal lumen and
then directly deposited to the NALT (nasal associated lymphoid
tissue) via M cell transcytosis [65], which preferentially drains into
lymph nodes. This process induces strong local (NALT) and
distant immune responses in both peripheral and mucosal immune
compartments [66]. In contrast, soluble antigens can penetrate the
nasal epithelium and directly interact with dendritic cells,
macrophages and lymphocytes and then these antigens are
transferred to posterior lymph nodes [67]. Soluble antigens can
bypass the NALT and be directly fed into superficial lymph nodes
by antigen presenting cells in the nasal lumen resulting in a lower
local immune response [66]. Therefore, VLP immunogens can
potentially interact directly with the mucosal immune system to
elicit high titer immunity.
Several approaches are in progress to develop vaccines against
H5N1 viruses. To date, products tested in humans have not been
effective at producing a strong immune response in a large
percentage of subjects tested in clinical trials [68]. However, many
of these previous H5N1 vaccine candidates were derived from
clade 1 or clade 3 isolates that required multiple doses and/or the
use of various adjuvants to achieve levels of antibodies believed to
correlate with seroprotection in a majority of subjects tested
[34,48,69–78]. Results presented in this report indicate that our
A/Indonesia/05/2005 (clade 2) VLP vaccine elicited higher HAI
antibody titers than the A/Viet Nam/1203/2004 (clade 1) VLP
vaccine without the use an adjuvant and elicited a robust and
broadly reactive immune response following two vaccinations.
Interestingly, a single immunization was able to protect mice from
virus-induced death, albeit mice administered lower doses of VLPs
or rHA had viral replication in the lungs and transient weight loss.
These results are similar to recent live attenuated vaccines that
required two vaccinations to prevent weight loss, but were able to
protect ferrets following a single vaccination [4]. The ability to
protect humans using a ‘‘one-shot’’ vaccination regimen is highly
desirable for a vaccine against influenza isolates with pandemic
potential. Following an outbreak, vaccines that reduce viral titers
in the lung and nasal mucosa may slow the transmission of the
virus among humans; there may not be sufficient time for a
booster shot of vaccine to achieve optimal antibody titers. The
VLP vaccine described in this report demonstrates that a one-dose
regimen is potentially possible in rodents using a non-replicating
Table 4. Pathological and Virological Analysis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vaccinea pfu/mlb Weightc Activityd Dyspneae Survivalf
VLP (2 doses) ,1.00E+02 98% 0 0 100%
rHA (2 doses) 6.00E+03 91% 0 0 100%
VLP (1 dose) ,1.00E+02 97% 0 0 100%
rHA (1 dose) 4.50E+04 86% 1 0 100%
Mock 1.57E+06 80% 2 1 0%
aVaccine (3 mg) administered at weeks 0 (1 dose) or week 0 and 3 (two doses).
bParticle forming untis (pfu) per milliliter (ml) in the lungs of mice at day 3 post-
challenge. ,1.00e+2 = viral titers less than 100 pfu/ml.
cPercentage of original weight at day 6 post-challenge.
dActivity score. 0 = Full activity. 1 = slow to respond to touch, but still mobile.
2 = little response to touch.
eDyspnea. 0 = no shortness of breadth. 1 = heavy breathing and shortness of
breadth.
fPercentage of mice that survived challenge at day 8 post-challenge.
doi:10.1371/journal.pone.0001501.t004..
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immunogen that can elicit cross-clade protective immune
responses and is worthy of evaluation in the clinic.
One of the challenges faced by influenza vaccine developers is the
ability to protect populations in the face of a spreading pandemic.
The next influenza pandemic may be caused by a H5N1 virus and if
so, it is not known which clade or subclade will be responsible.
Correlates for protection from infection by H5N1 isolates have not
been determined. Historically, the HAI assay is the most widely used
serological assay for monitoring influenza immunity and is the
accepted standard for measuring functional influenza-specific serum
antibodies to the hemagglutinin following vaccination. An HAI titer
that is greater than 1:40 ($40) against a seasonal influenza strain is
believed to be protective for ,50% of the vaccinated population
[18]. However, this does not appear to hold true for avian H5N1
viruses, since no correlation between HAI titer and protective
efficacy against H5N1 infection has been reported in animal or
human systems. Therefore, new correlates may be necessary to assess
the efficacy of potential H5N1 vaccines. One interesting finding in
this study was the correlation between the slower disassociation rates
of the VLP-elicited antibody to HA compared to antibodies
produced in response to rHA vaccines. In addition, antibodies
elicited to the homologous clade 2 rHA had faster association rates
compared to antibody binding the heterologous clade 1 rHA. The
increase in antibody association rates in vivo could bind HA on viruses
quickly and perhaps decrease the number of infected cells in the
lung, and thus could act to reduce the amount of viral replication to
allow the immune system opportunity to better control the infection.
In addition, antibodies that are slow to dissociate from the virion
may continue to reduce the ability to uncoat and thus restrict the
virus post-infection. Further analysis is needed; however, the use of
antibody association/dissociation rates may be a more accurate
assessment of vaccine efficacy that could potentially correlate with
enhanced efficacy.
One of the more interesting findings in this study was the
severity of disease induced by the 6:2 H5N1/PR8 reassortant
viruses in the BALB/c mouse model. Previous publications using
1997 H5N1/PR8 clade 3 reassortant viruses generated by
Subbarao and colleagues were not lethal for mice [79]. Therefore,
we were expecting the clade 1 and clade 2 reassortant viruses to
also be non-lethal and to be able to culture viruses from lungs of
infected mice to compare the efficacy of each vaccine based only
upon reduction of virus titers. Instead, we found both the clade 1
and clade 2 reassortant viruses to cause precipitous weight loss and
to be lethal for mice. However, lethality was only observed in mice
infected under deep anesthetic, since mice infected under lighter
anesthesia conditions showed less dramatic weight loss (,7%) and
no mortality (data not shown). Therefore, we speculate that these
reassortant viruses are lethal under conditions when the virus is
allowed to infect the lower respiratory tract. Interestingly, we
found that not all clade 2 H5N1/PR8 reassortant viruses were
lethal to mice, since mice administered a similar high dose (106
pfu/ml) of the PR8 reassortant viruses with HA and NA proteins
from A/Anhui/1/2005 (clade 2.3) did not cause mortality. In
addition, none of these reassortant viruses were lethal in a ferret
model (data not shown), which may be a reflection of the
difference in anatomy, sites of replication, and distribution of viral
receptors between BALB/c mice and ferrets. We acknowledge that
wild-type H5N1 isolates may result in more pathology in mice
compared to the H5N1 HA/NA reassortant viruses used in this
study. Many components of avian H5N1 isolates have been
attributed to the highly pathogenic nature of these viruses,
including the H5N1 PB2 and NS1 proteins, which are not
included in the H5N1-PR8 reassortant viruses used here.
Nonetheless, reassortant viruses can be useful tools to evaluate
immune responses raised to H5N1 HA and NA components in the
absence of a high containment facility and special permits required
to work with wild-type H5N1 viruses. We will soon have
additional capacity to be able to do future immunogencity studies
against highly pathogenic wild-type H5N1 isolates.
This is the first report of an H5N1 VLP vaccine derived from a
clade 2 influenza isolate. These clade 2 H5N1 VLP and rHA
vaccines elicited protection against a lethal challenge from an
antigenically similar reassortant virus strain without including an
adjuvant. However, rHA only vaccines, administered at the same
dose, did not prevent morbidity and weight loss following a cross-
clade challenge even though all animals did eventually recover. In
contrast, a 3 mg dose of VLPs provided cross-clade protection
against a H5N1 challenge with little to no observed weight loss. It is
reasonable to expect that use of VLP-based vaccines will provide
substantial clinical protection and reduce mortality in humans and
appropriate clinical studies should be initiated to further evaluate the
potential of VLP vaccines for both seasonal and pandemic influenza.
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